Testosterone undecanoate effects on cardiovascular risk factors in men with metabolic syndrome

• Main Authors: A. L. Vertkin, A. V. Naumov, L. Yu. Morgunov, S. Yu. Kalinchenko, E. V. Krivtsova, E. N. Arinina, E. S. Kolosova, Yu. S. Plupanova
• Format: Article
• Language: Russian
• Published: «SILICEA-POLIGRAF» LLC 2008-10-01
• Series: Кардиоваскулярная терапия и профилактика
• Subjects: metabolic syndrome; androgen deficiency; testosterone; cardiovascular risk factors; quality of life
• Online Access: https://cardiovascular.elpub.ru/jour/article/view/1104

Aim. To study testosterone undecanoate effects on some modifiable cardiovascular risk factors in men with metabolic syndrome (MS).Material and methods. Androgen status screening (anthropometry, total and free testosterone level measurement) was performed in 35-75-year-old men with cardiovascular disease (CVD). In 50 MS patients, a double-blind, randomized, placebo-controlled trial of testosterone undecanoate was performed, focusing on hypogonadism clinics, erectile function (EF), quality of life (QoL), lipid profile (LP), inflammatory markers: C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6).Results. In men with CVD, clinical and laboratory androgen deficiency was observed in 67,8%, more often in those with visceral obesity. By Week 30 of testosterone treatment, androgen deficiency became less manifested clinically; EF, QoL, and LP also improved. Baseline levels of inflammatory markers pointed to elevated CVD risk. Testosterone undecanoate therapy was associated with significant, 2-fold reduction in CRP concentration, and 1.2-fold decrease in TNF-alpha and IL-6 levels.Conclusion. In men with CVD, hypogonadism was widely prevalent; testosterone level was age-independent in combined pathology. Testosterone level normalization facilitated improvements in LP and QoL. Testosterone undecanoate therapy was safe and well-tolerated.